WO2016102716A1 - Nouveaux anticorps anti-adam17 humanisés - Google Patents

Nouveaux anticorps anti-adam17 humanisés Download PDF

Info

Publication number
WO2016102716A1
WO2016102716A1 PCT/EP2016/050029 EP2016050029W WO2016102716A1 WO 2016102716 A1 WO2016102716 A1 WO 2016102716A1 EP 2016050029 W EP2016050029 W EP 2016050029W WO 2016102716 A1 WO2016102716 A1 WO 2016102716A1
Authority
WO
WIPO (PCT)
Prior art keywords
humanized antibody
binding fragment
antigen binding
seq
cancer
Prior art date
Application number
PCT/EP2016/050029
Other languages
English (en)
Inventor
Peter Lowe
Sven Berger
Michael Tesar
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Priority to CN201680007889.3A priority Critical patent/CN107250162A/zh
Priority to JP2017534270A priority patent/JP2018502096A/ja
Priority to CA2971361A priority patent/CA2971361A1/fr
Priority to EP16700011.6A priority patent/EP3237008A1/fr
Priority to BR112017013420A priority patent/BR112017013420A2/pt
Priority to RU2017125036A priority patent/RU2017125036A/ru
Priority to KR1020177018568A priority patent/KR20170099927A/ko
Priority to AU2016204625A priority patent/AU2016204625A1/en
Priority to US15/538,331 priority patent/US20180057601A1/en
Priority to MX2017008475A priority patent/MX2017008475A/es
Publication of WO2016102716A1 publication Critical patent/WO2016102716A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • a germline represents the basic genetic message as is transmitted from parent to sibling prior to any functional rearangement in the coding sequence of said gene.
  • V variable
  • D diversity
  • J joining genes
  • Germline sequences for human V, D and J genes can be obtained and interrogated from curated databases such as IMGT, UNSWIg, NCBI and VBASE2.
  • sequences SEQ ID No. 7 and 8 are corresponding to consensus sequences wherein the potential back-mutations according to the invention are identified.
  • the antibody according to the invention may comprise none or at least one back mutation(s).
  • Another particular embodiment of the invention is a humanized antibody, or an antigen binding fragment thereof, characterized in that the light chain variable domain consists of the sequence SEQ ID No. 10, or any sequence exhibiting at least 80% identity with SEQ ID No. 10.
  • the humanized antibody comprising the light chain variable domain consisting of the sequence SEQ ID No. 10 above mentioned also comprises a heavy chain variable domain having the CDR-L1, CDR-L2 and CDR-L3 of sequences SEQ ID Nos. 1, 2 and 3, respectively.
  • the humanized antibody of the invention is characterized in that it inhibits with at least an IC 50 of 500 pM or less, preferentially 200 pM or less, the cellular shedding of at least one substrate of ADAM 17 selected from TNF-a, TGF-a, AREG and HB-EGF.
  • the humanized antibody is characterized in that it binds to an ADAM17 epitope with a Kd of about 10 nM or less, preferentially of about 5 nM or less, and more preferentially of about 2 nM or less, as determined by surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • said cancer is a cancer chosen among estrogen-related breast cancer, non-small cell lung cancer, colon cancer and/or pancreatic cancer.
  • Expressed antibodies were adjusted to pH 7.5 and purified on protein A sepharose columns with elution by pH shift with Glycine, HC1 0.1 M, pH 3, the resulting eluant was adjusted to pH 7.5 by dialysis against Tris-HCl pH 7.5 solution.
  • the protein solutions were normalised by total protein quantification using the bicinchoninic acid assay. Equal quantities of protein were separated by SDS-PAGE in non-reducing conditions, and visualised by GelCode Blue Safe Protein Stain (BioRad).
  • Four humanised variants were analysed for germline combination IGHV2-5 and IGKV1-33, Vl-4, and thirteen variants with germlmes IGHV4-4 and IGKV1-39, V5-V17 and hzl022C3.
  • hzl022C3 showed a significantly increased inhibition of the release of AREG-Nluc, TGFa-Nluc or HB-EGF-Nluc than ml022C3 (+6.35% ⁇ 1.47%; +6.12% ⁇ 1.13% and +10.15% ⁇ 2.99%) respectively) (figures 2A-2C respectively).
  • ADAM 17 expression levels were determined by staining, lxl 0 5 cells/ 100 ⁇ in FACS buffer (PBS containing 1% BSA and 0.01% sodium azide) incubated for 20 min. at 4°C with increasing concentrations of the MAB9301 (Clone 1 1 1633, R&D systems) in order to determine a saturating concentration. Cells were then washed three times in FACS buffer. Cells were resuspended and incubated for 20 min. at 4°C with a goat anti-mouse IgG-Alexa 488 antibody (Invitrogen Corporation, Scotland, # A1 1017). Cells were then washed three times in FACS buffer.
  • FACS buffer PBS containing 1% BSA and 0.01% sodium azide
  • the CaOV3 xenograft model was set up by cell engraftments on SCID mice as described above.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un nouvel anticorps humanisé capable de se lier à ADAM-17, ainsi que les séquences d'acides aminés et d'acides nucléiques codant pour ledit anticorps. Dans un aspect, l'invention concerne un nouvel anticorps humanisé ou des fragments de liaison de l'antigène capables de se lier à ADAM-17 et présentant des activités anti-tumorales. L'invention concerne également l'utilisation dudit anticorps humanisé en tant que médicament pour le traitement du cancer. L'invention concerne en outre des compositions comprenant ledit anticorps humanisé, seul ou combiné ou conjugué à d'autres composés anticancéreux, et leur utilisation pour le traitement du cancer.
PCT/EP2016/050029 2014-12-24 2016-01-04 Nouveaux anticorps anti-adam17 humanisés WO2016102716A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201680007889.3A CN107250162A (zh) 2014-12-24 2016-01-04 新的人源化adam17抗体
JP2017534270A JP2018502096A (ja) 2014-12-24 2016-01-04 新規ヒト化ａｄａｍ１７抗体
CA2971361A CA2971361A1 (fr) 2014-12-24 2016-01-04 Nouveaux anticorps anti-adam17 humanises
EP16700011.6A EP3237008A1 (fr) 2014-12-24 2016-01-04 Nouveaux anticorps anti-adam17 humanisés
BR112017013420A BR112017013420A2 (pt) 2014-12-24 2016-01-04 anticorpo adam17 humanizado
RU2017125036A RU2017125036A (ru) 2014-12-24 2016-01-04 Новое гуманизированное антитело к adam17
KR1020177018568A KR20170099927A (ko) 2014-12-24 2016-01-04 신규 인간화 ａｄａｍ17 항체
AU2016204625A AU2016204625A1 (en) 2014-12-24 2016-01-04 Novel humanized ADAM17 antibody
US15/538,331 US20180057601A1 (en) 2014-12-24 2016-01-04 Novel humanized adam17 antibody
MX2017008475A MX2017008475A (es) 2014-12-24 2016-01-04 Novedoso anticuerpo humanizado adam17.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14307185 2014-12-24
EP14307185.0 2014-12-24

Publications (1)

Publication Number Publication Date
WO2016102716A1 true WO2016102716A1 (fr) 2016-06-30

Family

ID=52396391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/050029 WO2016102716A1 (fr) 2014-12-24 2016-01-04 Nouveaux anticorps anti-adam17 humanisés

Country Status (11)

Country Link
US (1) US20180057601A1 (fr)
EP (1) EP3237008A1 (fr)
JP (1) JP2018502096A (fr)
KR (1) KR20170099927A (fr)
CN (1) CN107250162A (fr)
AU (1) AU2016204625A1 (fr)
BR (1) BR112017013420A2 (fr)
CA (1) CA2971361A1 (fr)
MX (1) MX2017008475A (fr)
RU (1) RU2017125036A (fr)
WO (1) WO2016102716A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021061A1 (fr) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Anticorps humanisés anti-pd-1 et leurs utilisations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018124785A1 (de) 2018-10-08 2020-04-09 Schott Ag Glas mit vorzugsweise erhöhter speicherbarer Zugspannung, chemisch vorgespannter Glasartikel mit vorzugsweise erhöhter speicherbarer Zugspannung, Verfahren zu dessen Herstellung sowie dessen Verwendung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104581A1 (fr) * 2011-02-01 2012-08-09 Cancer Research Technology Limited Molécules d'anticorps anti-tace et leurs utilisations
WO2014157229A1 (fr) * 2013-03-28 2014-10-02 国立大学法人東北大学 Epitope peptidique tace, anticorps protéique anti-tace humain et hybridome produisant des anticorps

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036445A1 (fr) * 1999-11-18 2001-05-25 The Brigham And Women's Hospital, Inc. Compositions et procedes pour un diagnostic et un traitement ameliores des tumeurs des cellules germinales
EP1449538A1 (fr) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de TACE ou amphirégulin pour moduler la transactivation de signaux récepteur EGF
AU2005316217A1 (en) * 2004-12-17 2006-06-22 Memorial Sloan Kettering Cancer Center Regulation of metalloprotease cleavage of cell surface proteins
US9845482B2 (en) * 2011-06-29 2017-12-19 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104581A1 (fr) * 2011-02-01 2012-08-09 Cancer Research Technology Limited Molécules d'anticorps anti-tace et leurs utilisations
WO2014157229A1 (fr) * 2013-03-28 2014-10-02 国立大学法人東北大学 Epitope peptidique tace, anticorps protéique anti-tace humain et hybridome produisant des anticorps

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Science", 1985, MACK PUBLISHING COMPANY
CHEN Y. ET AL., J MOL BIOL., vol. 293, no. 4, 1999, pages 865 - 81
LEFRANC M.-P., IMMUNOLOGY TODAY, vol. 18, 1997, pages 509
LEFRANC M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LEFRANC, M.-P.; POMMIE, C.; RUIZ, M.; GIUDICELLI, V.; FOULQUIER, E.; TRUONG, L.; THOUVENIN-CONTET, V.; LEFRANC, DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
STEWARD ET AL.: "Solid phase peptides synthesis", 1984, PIERCE CHEM. COMPANY
TATUSOVA ET AL.: "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", FEMS MICROBIOL., vol. 174, 1999, pages 247 - 250

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020021061A1 (fr) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Anticorps humanisés anti-pd-1 et leurs utilisations

Also Published As

Publication number Publication date
AU2016204625A1 (en) 2017-07-13
CA2971361A1 (fr) 2016-06-30
MX2017008475A (es) 2018-02-21
EP3237008A1 (fr) 2017-11-01
BR112017013420A2 (pt) 2018-02-06
CN107250162A (zh) 2017-10-13
KR20170099927A (ko) 2017-09-01
US20180057601A1 (en) 2018-03-01
JP2018502096A (ja) 2018-01-25
RU2017125036A (ru) 2019-01-24

Similar Documents

Publication Publication Date Title
CN112601762B (zh) 抗cd47抗体及其应用
US20200255516A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
US20230090014A1 (en) Anti-cd47/anti-pd-l1 antibody and applications thereof
EP3086808B1 (fr) Anticorps anti adam17 et leur utilisation dans le traitement du cancer
US20180057601A1 (en) Novel humanized adam17 antibody
JP2023109923A (ja) グロボｈに対するヒト化抗体および癌治療におけるその使用
TW202200620A (zh) 抗flt3抗體及組合物
CN114685657A (zh) 一种功能增强型抗体阻断剂的开发及其应用
JP2022517216A (ja) 組換え抗ヒトｐｄ－１抗体およびその用途
WO2021013061A1 (fr) Anticorps anti-vegfr2 humanisé et son utilisation
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
TW202413414A (zh) 抗ｉｌｔ４抗體及其醫藥用途
TW202214705A (zh) 抗tigit抗體及雙抗體和它們的應用
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16700011

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2971361

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15538331

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2017534270

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/008475

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017013420

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20177018568

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016204625

Country of ref document: AU

Date of ref document: 20160104

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2016700011

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017125036

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017013420

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170621